|
Name |
Chartarlactam F
|
Molecular Formula | C23H31NO4 | |
IUPAC Name* |
(3R,4aS,7R,8R,8aS)-3,4'-dihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-6,7-dihydro-3H-furo[3,2-g]isoindole]-8'-one
|
|
SMILES |
C[C@@H]1CC[C@@H]2[C@@]([C@@]13CC4=C(C=C5CNC(=O)C5=C4O3)O)(CC[C@H](C2(C)C)O)C
|
|
InChI |
InChI=1S/C23H31NO4/c1-12-5-6-16-21(2,3)17(26)7-8-22(16,4)23(12)10-14-15(25)9-13-11-24-20(27)18(13)19(14)28-23/h9,12,16-17,25-26H,5-8,10-11H2,1-4H3,(H,24,27)/t12-,16+,17-,22+,23-/m1/s1
|
|
InChIKey |
NSKHZIOXIKSFER-NIVYWPPISA-N
|
|
Synonyms |
Chartarlactam F; CHEMBL3104990
|
|
CAS | NA | |
PubChem CID | 73891074 | |
ChEMBL ID | CHEMBL3104990 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 385.5 | ALogp: | 3.7 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 78.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 28 | QED Weighted: | 0.623 |
Caco-2 Permeability: | -4.859 | MDCK Permeability: | 0.00000697 |
Pgp-inhibitor: | 0.012 | Pgp-substrate: | 0.968 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.143 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.25 | Plasma Protein Binding (PPB): | 95.91% |
Volume Distribution (VD): | 1.509 | Fu: | 7.11% |
CYP1A2-inhibitor: | 0.492 | CYP1A2-substrate: | 0.791 |
CYP2C19-inhibitor: | 0.282 | CYP2C19-substrate: | 0.314 |
CYP2C9-inhibitor: | 0.74 | CYP2C9-substrate: | 0.918 |
CYP2D6-inhibitor: | 0.748 | CYP2D6-substrate: | 0.598 |
CYP3A4-inhibitor: | 0.257 | CYP3A4-substrate: | 0.228 |
Clearance (CL): | 10.285 | Half-life (T1/2): | 0.4 |
hERG Blockers: | 0.058 | Human Hepatotoxicity (H-HT): | 0.481 |
Drug-inuced Liver Injury (DILI): | 0.035 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.985 | Maximum Recommended Daily Dose: | 0.972 |
Skin Sensitization: | 0.882 | Carcinogencity: | 0.068 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.37 |
Respiratory Toxicity: | 0.944 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002996 | 1.000 | D0L2LS | 0.279 | ||||
ENC003789 | 1.000 | D0Z1XD | 0.278 | ||||
ENC002673 | 0.812 | D0Q6NZ | 0.277 | ||||
ENC005396 | 0.812 | D03XOC | 0.274 | ||||
ENC003020 | 0.812 | D08QKJ | 0.272 | ||||
ENC003012 | 0.773 | D0U3GL | 0.266 | ||||
ENC002009 | 0.773 | D0I2SD | 0.261 | ||||
ENC003552 | 0.753 | D04GJN | 0.261 | ||||
ENC003008 | 0.723 | D09IPV | 0.254 | ||||
ENC003014 | 0.670 | D08QMX | 0.252 |